Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Proof of Concept Study to Evaluate Multiple Gait and Balance Parameters After Withdrawal of Dalfampridine-ER 10mg in Subjects With MS

NCT01535664 is registered in ClinicalTrials.gov with Acorda Therapeutics as lead sponsor.

NCT NCT01535664
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01535664 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Proof of Concept Study to Evaluate Multiple Gait and Balance Parameters After Withdrawal of Dalfampridine-ER 10mg in Subjects With MS
Lead sponsor
Acorda Therapeutics
Phase
Observational
Overall status
Completed
Start date
January 31, 2012
Completion date
June 30, 2012
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis